Esperion Therapeutics, Inc. (ESPR) Monday announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Ltd. to resolve a patent litigation. As per the agreement, Micro Labs has agreed not to market a generic version of Nexletol in the United States prior to April 19, 2040.
Esperion, a commercial stage biopharmaceutical company, has earlier filed a patent infringement lawsuit against the Micro Labs. The litigation was in response to Micro Labs' filing of Abbreviated New Drug Application seeking approval to market a generic version of Nexletol, prior to the expiration of the applicable patents.
Esperiod has ongoing patent litigation against the remaining defendants Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited, Dr. Reddys Laboratories Inc., Hetero USA Inc., MSN Pharmaceuticals Inc., Renata Ltd. and Sandoz Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.